globally. ENT start ENT No after materially business and an you impact safe Good late love and the thank XXXX had everyone, March or greatly ENT’s no year. visits to exception. is pandemic’s Intersect pandemic adversely hospitals industry the to With elective a and and immune in revenues and has earnings today's are procedures sincerely I February, office you, been reduced, effects impacted suspending surgical joining that your solid you, the Randy. families has were Intersect ENT Thank call. Intersect lives afternoon, Since on hope ones for COVID-XX QX adverse and healthy.
the we such enrollments felt XXXX. market for that XXXX. year-on-year we top-line also clinical strategies our the and laying of through revenue confident on inventory, February, commercial other began execution reflected foundation selling and leading growth rhinosinusitis and while we novel access as indicators of a performance the in development part market improve working in treating to January access latter our for our and XXXX procedure chronic were channel focusing progress of solid By solutions revenue In
outbreak Despite and we start US year revenues million late robust March down in to $XX.X in making. our first progress million preannouncement were year-ago period. reversed with early ended of the from the a quarter which However, the February $XX.X COVID-XX earlier at was consistent in the the QX XXXX and
that for that the future, successfully Deerfield pandemic million response With taken note introduction announced Today, comment my actions this basis privately in morning's like status a with closed the as we Company. Management to capital optimism raise. formed discuss to the in financing continued initiatives on placed convertible we briefly I growth the and have would our before of $XX and I
of include rate terms a The price basic conversion and that X% matures a $XX.XX in XXXX. coupon
as While the would X-K I release to details. security contains other you filing features, for refer callability, full press such the and the
and manage announced discuss invest growth largest enhance provide through incremental challenges capital raised, corporate and space. as our leader pleased very the our with ability us with who Intersect ENT will to while well-positioned to belief with strength, our liquidity I of our shortly, actions markets, financial work pandemic capital to that are remains that to a investors our needs. additional products. initiatives, growth wherewithal ENT one we without We grow able and flexibility, previously the accelerate provides share This the the capital business, to the our in The future us resources return continuing any with coupled remaining are build that market in to of the
ensure employees and visits. office the roles, and travel, pandemic, from the non-essential me and the to based, health field the the while nearly was to business ENT address to home customers return work took position all COVID-XX of field transitioned start limited office immediate team’s the pandemic. we At we We greatly safety and serve. curtailing actions the let to and all of Intersect Now, response quarter first our
will continue appropriate members to long the We is the all as ENT to as are of take that safe. ensure it precautions necessary Intersect family
Operationally, to near-term and we sought to to reduce liquidity, cash us the and our proactively shortfall. immediate costs, preserve maintain revenue enable navigate
range be at of early part an additional These in manufacturing. reductions reducing all The strategy were workforce across employees. Furloughs to levels. our actions cash in X% enacted we reduce of as our specific, April. the cost actions approximately and To of more included our burn, workforce made were furloughing reduction by and XX% a organization primarily
we to as sought restoring of importance Importantly, our and in strongly customers. the We the business organization, procedures and field our our elective impact coverage to of to revenue and to minimize selling our quickly resume. investors recognized
and broaden aiming spans while to savings have territories physician any to possible control where realignment We seeking completed at to the of delayer and of impact local to coverage realize the regions minimize level.
expenditures addition, given note, executing company. projects difficulty reduced In the discretionary clinical and we the in expenses our in of studies delayed pandemic. the operating field research across we in the capital the Of context XXXX in
as hold, inventory while inventory also halt while finished us on enables our drawing six we strategic further historical our quickly We goods inventory. manufacturing needs production, down conditions cash normalize. meet that we manufacturing. demand, can versus near-term will of position, we suspended a With preserve begin With to customer temporarily asset as knowing to months view
have operations shift maintain restart production will full current on limited manufacturing a direct clear, a in including critical summer. to required position we appropriate and time. at the the leadership and skilled labor, be Based capacity production readiness through who of expectations, our manufacturing our anticipate at capabilities the we production be To retained
cost under million Having April, cash early initiatives of QX QX $XX savings lowered million of approximately scenarios reduction protracted the these goals The net a $XX at well we successfully of nearly close of through planned modeled of our of capitalized downside result believe balance more COVID-XX. in we our by cash from impact use XXXX. our with accomplished March, combined even of were
that and would be expense on pressures, where near-term an better the we our and raise determined addressed we ensure success needed. our cash focus to capital though future even us -- would invest incremental allow and However,
with and month, During engaged variety evaluated we we Goldman of a announced options, convertible the structure Sachs the debt last potential in today. capital resulting
in structure, liquidity while of through we Now, with strength cost we as overall investment a have capital, at $XX more March believe the new least XXXX. prudent and financial coming out an balances ensuring our existing of sound million business today additional and drive to cash
of drive retrain by success, ENT, to better was commercial this Intersect commitment a the organization. commercial the where opportunity we compliantly genuinely and access across spirit We country, most unprecedented that leaner, emerge like possibility of to proud are as for transform true growth. entire and especially efforts I and integrate a and circumstance in now transition and innovation singularly quick focused on our organizations train customers. opportunity and to as of stronger our use the virtually. patients we commercial We working and benefit against better exhibited With am the advancement this so and equipped unique and market driving embrace organizations the payer organization.
team. built University field robust University, XENT virtual elevate Intersect effectiveness of to curriculum a the and ENT We instituted sales also our
workflows by manufacturing. aligning better have research innovation side, regulatory, key our we and and processes product clinical new development the in functions strengthened contributing On development, and
We in have despite been idle not sheltering place.
at today, geographies in rates look across see we are signs country. different procedures clear the As albeit, the elective opening, market we that at different
safety and that ensure to continue procedures course and practices as well-being of will up. We our employees of open
in our invest rebound of advantage revenue development intend of But procedures market to quickly. renewed growth take the goal aggressively we in the elective to eventual initiatives with achieving
then as QX in and we expect as versus year-on-year May we're First eventually consistently versus in going quarter-to-quarter forward. April, month-to-month seeing growth QX
the value Prior to customers clinical each realizing strong significant the were and the PROPEL clinical that product's our utility. of underscores and evidence pandemic, SINUVA
back As revenues as the needs our reimbursement to with XXXX, benefits. It analytical meet will and our line was our improvement insight, in of that meaningful market February key our of unique the while tracking prior strengthened expanding our infrastructure begin we expectations development in-office and our market XXXX in with and and clear execution noted, actions were commercial year guidance. the products. year sales in ahead of support through selling such capabilities In half market improved force access
such data These heightened for in and points, January in February. as positive resulted enrollments strategies SINUVA
aggressively resume, efforts look most are sales As to market our traction procedures we'll ENT largest our the rebounds in talented and surgeries the among office we and knowledgeable based the redouble are by strategies industry. respected and which XXXX, the and force is and gaining using in these against early elective encouraged we
elective mid-term ENT in the confidence What rebound adds near further ability procedure to is to the to Intersect of landscape. my sinus
medical sinusitis rather elective our the XX% unmet than and procedures or of their surprising it's the delayed quarter care. needs, untreated the of to were beginning many approximately sinus and of field that market with the that will procedures not nature sufferers a meaningfully estimate third for patients canceled. and the Given postponed second sinus chronic reopen backlog for that We surveys end of XX% of at awaiting quarter persistence indicate otherwise
based office PROPEL based the hospital such implant, of procedures, such earlier ahead anticipate procedures SINUVA We as as return implant. will
to The use. smaller are a post-COVID traditional procedures or represents care of hospital centers OR seeing excellent shift ambulatory adoption site opportunity surgeries for from while penetration drive SINUVA also and expanding trial in already and preparing ASCs. towards an landscape We surgical PROPEL
the and will term. return PROPEL remains to access clinical that more the benefit are OR compelling in surgical near ASC hospital PROPEL limited though may be We of procedures the confident as
to achieve recovery SINUVA near expect in mid-term return year-end. We by use levels expanded and the full the and to historic PROPEL’s of
to for an as go health forward, portfolio. support we increasing economic our Importantly, we evidence see role
stated we’ve and via unencumbered physicians ensure payer to for to As products appropriate procure That to makes last our products. it we call, access our and want institutions use easy on reimbursement. quarter's
increased use of J commercial will the to of code use continue both in-office capitalize and payer We SINUVA PROPEL. for on
several early use which schedule of payers In and January national we for benefits. showing code fact from the J favorable received commercial February, fee in treatment was
elective draw market as coverage to We intend improved resume. upon procedures sinus the
emerging addition, ASC the for also environment. out In in carve opportunities see expanding to we reimbursement PROPEL
efforts to in opportunities gain scale, our are markets time as Illinois. While a some and Texas realized national take emerging on to there immediate be key traction such will fully
economic reimbursement. health to future preparing are we Lastly, influence studies
data registry, expedite use is Our sources real-world to reimbursement proof and portfolio. the initial across evidence appropriate the supporting view to
framework long-term health We central to growth. studies as also of prospective for long-term sustained assessing vision evidence are our benefit the are potential reimbursement economic and
to and expanded therapies benefits unencumbered PROPEL and centered majority clinical coverage central SINUVA standard together, on vast Taken access making available to of and are our of vision payer the of and care patients.
have a meeting the and by submission in we earlier endpoint the regarding We trial. a regard had an for January informed and products program. is strengths quarter, PMA we path clear With our in of innovation new balloon our clinical to FDA positive our established aligned believe drug-coated with ASCEND forward with that
thereby, We us meet FDA with enabling lock the down expect again clinical in requirements. to our June, remaining to
research of we are of remainder as the through drug-coated However, of clear pivotal part the submission preservation associated noted, a the year. risk pandemic. to trial be at our balloon initiatives the until of for imprudent I we supporting initiate new products look clinical would the certain delaying cash clinical It are
support half aggressively in equate strategies deploying We to execution Overall, work on the are reinitiating closer signs in believe progress us XXXX commercial and we XXXX. development revenues. drug-coated second market actions sound in turn XXXX. relative expect market access improvement a will revenue achieve to and to growth already balloon which This launch our enable XXXX to the resources clinical begin showing to the our would to year-end of of
depth customers procedures company elective to action to and risks length savings, our to taking and resume. costs that key While with are can decisive subject be a this so re-engage strong pandemic, Booming cash related the of in is we the the now position once
capital the and solid position announced position of at positioned us COVID-XX drive today well and through challenge have growth. as A renewed infusion manage capital March revenue additional solidify the an end of financial we of to our
us the in our and actions and our offerings, a product commercial ENT confidence market space. the strengthen our prospects company's in of of role results strength combined position strategies organization, talent financial the the future The have taken early in the give positive pipeline and as to to leader we our the
you me Let take results. turn to through Randy to the financial our now over call
